89bio, Inc. Deferred Tax Assets, in Process Research and Development
89bio, Inc. had Deferred Tax Assets, in Process Research and Development of $119.43 million as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2025-02-27
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $119.43M.
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $41.83M.
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $18.93M.
- 2021-12-31: Deferred Tax Assets, in Process Research and Development $6.53M.
| Period end | Deferred Tax Assets, in Process Research and Development | Deferred Tax Assets, in Process Research and Development as first filed |
|---|---|---|
| 2024-12-31 | $119.43M 10-K · filed 2025-02-27 | |
| 2023-12-31 | $41.83M 10-K · filed 2025-02-27 | |
| 2022-12-31 | $18.93M 10-K · filed 2024-03-01 | |
| 2021-12-31 | $6.53M 10-K · filed 2023-03-15 | |
| 2020-12-31 | $5.39M 10-K · filed 2022-03-24 | |
| 2019-12-31 | $3.42M 10-K · filed 2021-03-25 | $3.33M 10-K · filed 2020-03-18 |
| 2018-12-31 | $1.97M 10-K · filed 2020-03-18 |